Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 15, Issue 5 (September 2013) 15, 590–591; 10.1038/aja.2013.85

A 32-gene risk index: a new prognostic approach for prostate cancer progression

Chao Cai1,2, Wei-De Zhong3, W. Scott McDougal1 and Chin-Lee Wu1,4

1Department of Urology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
2Graduate School of Southern Medical University, Guangzhou, Guangdong 510515, China
3Department of Urology, Guangzhou First Municipal People's Hospital, Guangzhou, Guangdong 510180, China
4Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

Correspondence: Dr CL Wu, (cwu2@partners.org)

10 June 2013

Abstract

Radical prostatectomy (RP) has been a widely accepted and standard treatment for clinically localized and locally advanced prostate cancer. However, effective clinical management of RP patient remains being challenged, given that conventional prognostic factors, including Gleason score, pT stage, surgical margin status and presurgery serum prostate-specific antigen (PSA), cannot correctly predict cancer recurrence after RP. Recently, a robust prognostic model for biochemical recurrence (BCR) and metastasis has been developed by our group at the MGH. This model was a continuous risk index based on the expression of 32 genes and was validated in an independent, blinded cohort of 270 RP patients. In multivariate analyses, the 32-gene risk index model was prognostic for risk of BCR and had added value over the traditional parameters. This model may contribute to accurate postoperative treatment decision and hopefully help patients and doctors make a more reasonable selection at the stage of a positive biopsy.

PDF |

 
Browse:  883
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved